GlobeNewswire Inc.Jun 15, 9:00 AM ET▲ Positive
The company successfully cleared FDA review for its IND application without clinical hold, enabling U.S. patient enrollment. This represents a significant milestone for the company's rheumatology program and vilamakitug development, demonstrating regulatory progress and advancement toward potential commercialization of a next-generation IL-1α antibody targeting an unmet medical need.